Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Future Fund LLC

Future Fund LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 58.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,596 shares of the biopharmaceutical company's stock after purchasing an additional 6,500 shares during the period. Halozyme Therapeutics makes up approximately 2.4% of Future Fund LLC's holdings, making the stock its 20th largest holding. Future Fund LLC's holdings in Halozyme Therapeutics were worth $841,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth $29,000. Smartleaf Asset Management LLC boosted its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $69,000. Parkside Financial Bank & Trust grew its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 173.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after buying an additional 1,028 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Stock Up 0.3 %

Shares of HALO traded up $0.17 during midday trading on Thursday, hitting $61.06. The company had a trading volume of 992,126 shares, compared to its average volume of 1,313,050. The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.42 and a beta of 1.32. The company's 50 day moving average price is $56.50 and its 200 day moving average price is $54.71. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

HALO has been the subject of several recent research reports. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $62.78.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now directly owns 33,611 shares of the company's stock, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 over the last 90 days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.